Type
Internal restructuring
Country
World
Region
Location of affected unit(s)
Germany, Israel, other locations
Sector
(10 - 33) Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

2,400 jobs
Number of planned job losses
Job loss
Announcement Date
8 May 2025
Employment effect (start)
8 May 2025
Foreseen end date
31 December 2026

Description

Teva, the Israeli-American pharmaceutical company, has announced plans to cut around 2,400 jobs worldwide by 2027.

In Germany, about 150 jobs Teva 2025-DE will be cut at at its headquarters in Ulm and its production site in Blaubeuren-Weiler. 50 jobs were already cut in the spring, and a further 150 jobs are to be cut by the end of 2026. The jobs are to be cut mainly through termination agreements with severance payments and not filling vacant positions; redundancies are not currently planned.

In Israel, between 250 and 300 jobs will be affected; voluntary retirement in line with existing union agreements will be offered.

The measures are part of its ‘Pivot to Growth’ restructuring plan announced in 2023. The move aims to deliver $700 million in cost savings by streamlining operations, consolidating manufacturing, and modernising processes with tools such as artificial intelligence. Teva currently operates 35 production sites, which it intends to reduce to fewer than 30 by 2027.

The company employs about 30,000 people worldwide.


Sources

Citation

Eurofound (2025), Teva, Internal restructuring in World, factsheet number 203260, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/203260.